Enoxaparin in unstable angina patients who would have been excluded from randomized pivotal trials
Jean-Philippe Collet, MD, PhD*,
Gilles Montalescot, MD, PhD*,*,
Erika Fine, MD*,
Jean-Louis Golmard, MD, PhD ,
Miles Dalby, MD*,
R.émi Choussat, MD*,
Annick Ankri, MD ,
Raphaëlle Dumaine, MD*,
Claude Lesty, PhD*,
Nicolas Vignolles, BSc* and
Daniel Thomas, MD*
* Institut de Cardiologie, Centre Hospitalier Universitaire Pitié-Salpêtrière (AP-HP), Paris, France
Department of Biostatistics, Pitié-Salpêtrière Hospital, Paris, France
Hemostasis Laboratory, Pitié-Salpêtrière Hospital, Paris, France

View larger version (31K):
[in a new window]
|
Figure 1 Flow chart of patients in the PARIS registry, including definitions of exclusion criteria and the number of patients in each category. Creat. Clear. = creatinine clearance; Hb = hemoglobin; LBB = left bundle branch block; NSTEMI = nonST-segment elevation myocardial infarction; UA = unstable angina.
|
|

View larger version (27K):
[in a new window]
|
Figure 2 Anti-Xa activity in excluded and non-excluded patients measured after the third injection or just before the coronary angiogram. The distribution of anti-Xa activity matches perfectly in both groups. Nearly all patients (94.4%) had an anti-Xa level above the lower limit of the therapeutic range (0.5 IU/ml), most of them being close to the upper limit (1 IU/ml).
|
|

View larger version (28K):
[in a new window]
|
Figure 3 Rates of bleeding events at 30 days in excluded and non-excluded patients. There were no significant differences between the two groups.
|
|

View larger version (22K):
[in a new window]
|
Figure 4 Rates of major coronary events at 30 days in excluded and non-excluded patients. **p < 0.001 between the two groups.
|
|
|